Last update June 5, 2024
Limited compatibility
We do not have alternatives for L01XX25.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
L01XX25 is Bexarotene in ATC Code/s.
Is written in other languages:L01XX25 belongs to these groups or families:
Variable | Value | Unit |
---|---|---|
Molecular weight | 349 | daltons |
Protein Binding | 99 | % |
Tmax | 2 | hours |
T½ | 7 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Bexarotene is a retinoid X receptor agonist used for cutaneous manifestations of T-cell lymphoma in patients who have not responded well to prior systemic therapy. Oral administration as a single daily dose.
At the time of the last update, we found no published data on its excretion in breast milk.
Its high binding to plasma proteins makes its passage into breast milk unlikely.
It is known from pharmacokinetics that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ 94%, after 5 T½ 96.9%, after 6 T½ 98.4% and after 7 T½ 99%. After 7 T½ the plasma concentrations of drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period to resume breastfeeding. (Anderson 2016)
Taking the published T½ of this drug (7 hours) as a reference, these 5 T½ would correspond to 35 hours. Due to significant adverse effects (FDA 2015, EMA 2006), it would be advisable to wait 7 T½ which would correspond to 2 days. In the meantime, express and discard breast milk regularly. Since administration is daily, these waiting times make it impossible in practice to continue breastfeeding.
See below the information of this related product: